Antitumor effect of polysaccharide TC-13 on allogeneic and syngeneic tumors in mice.
The antitumor activity of TC-13, a protein-bound polysaccharide extracted from a rare actinomycetes was tested on allogeneic and syngeneic tumors in mice. In the allogeneic Ehrlich carcinoma system, TC-13 showed antitumor activity over a broad optimal dose range, when administered by various routes such as ip, iv, sc, it (intratumorally) or po, even when given before tumor inoculation. TC-13 showed synergistic antitumor effects in combination with other immunomodulators, e.g., lipopolysaccharide, lentinan and picibanil. It showed antitumor activity against syngeneic tumors, MM46 mammary carcinoma and MCS-8 and Meth A fibrosarcoma.
D000818:Animals; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D005354:Fibrosarcoma / Q000188:drug therapy; D006020:Glycopeptides; D006023:Glycoproteins / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D006020:Glycopeptides; D006023:Glycoproteins; C035790:TC 13